10-Q: Inflection Point IV to Merge with Merlin Labs

Inflection Point Acquisition Corp. IV announces a definitive business combination agreement with Merlin Labs, Inc., alongside management changes and financing updates.

Summary

• Inflection Point Acquisition Corp. IV (f/k/a Bleichroeder Acquisition Corp. I), a blank check company, has entered into a Business Combination Agreement with Merlin Labs, Inc. on August 13, 2025.
• Upon closing, Inflection Point will merge with Merlin Labs, with Merlin Labs continuing as the surviving company, and the combined entity will be renamed Merlin Labs, Inc.
• The aggregate consideration for Merlin Labs Equity Holders (excluding certain convertible notes and warrants) is $800,000,000, payable in shares of New Merlin Labs Common Stock.
• Merlin Labs secured approximately $78 million in Pre-Funded Convertible Notes and warrants from Pre-PIPE Investors prior to the business combination agreement.
• An accredited investor has committed to a $50,000,000 Series A Preferred Stock Investment in New Merlin Labs, purchasing 4,901,961 shares of Series A Preferred Stock and warrants.
• The company reported a net income of $83,694 for the three months ended September 30, 2025, and $4,809,256 for the nine months ended September 30, 2025.
• Interest earned on investments held in the Trust Account amounted to $2,685,470 for the three months and $7,973,982 for the nine months ended September 30, 2025.
• As of September 30, 2025, cash was $1,049,403, and investments held in the Trust Account totaled $259,730,180.
• The company has a working capital deficit of $1,794,983 as of September 30, 2025.
• Management changes effective July 10, 2025, included new appointments for President & CEO, CFO, and COO, and changes to the Board and Audit Committee.
• The company's Amended and Restated Memorandum was amended on October 21, 2025, to change its name and allow for earlier redemption of Public Shares to facilitate a business combination.
• The underwriters' cash underwriting fee payment schedule was amended on August 5, 2025, deferring the remaining $1,000,000 until September 1, 2026.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the announcement of a definitive business combination agreement with Merlin Labs and significant pre-merger financing. However, the company's going concern warning, working capital deficit, and the inherent risks of SPAC transactions temper the overall sentiment.

Positives

• A definitive Business Combination Agreement has been signed with Merlin Labs, Inc., providing a clear path for the SPAC's purpose.
• The company generated significant non-operating income from interest on investments held in the Trust Account, totaling $7,973,982 for the nine months ended September 30, 2025.
• Net income for the nine months ended September 30, 2025, was $4,809,256, a positive shift from a net loss in the prior year's inception period.
• Merlin Labs secured approximately $78 million in Pre-Funded Convertible Notes and warrants, and a $50,000,000 Series A Preferred Stock Investment, indicating investor confidence in the target company.

Negatives

• The company has a working capital deficit of $1,794,983 as of September 30, 2025, indicating a need for additional capital for operations outside the Trust Account.
• Cash balance decreased from $2,107,309 at December 31, 2024, to $1,049,403 at September 30, 2025.
• General and administrative expenses increased significantly to $3,212,856 for the nine months ended September 30, 2025, compared to $77,427 for the prior year's inception period.
• The company faces substantial doubt about its ability to continue as a going concern due to its liquidity condition and the mandatory liquidation if a Business Combination is not completed by November 6, 2026.

Risks

• Inability to complete the initial Business Combination within the Completion Window (by November 4, 2026) or the Nasdaq 36-Month Requirement, leading to mandatory liquidation and potential delisting.
• Significant dilution of equity interest for Initial Public Offering investors if additional shares are issued in connection with a Business Combination.
• Subordination of Class A Ordinary Shares if preference shares are issued with senior rights.
• Potential for a change in control if a substantial number of Class A Ordinary Shares are issued, which could affect net operating loss carryforwards and lead to management changes.
• Adverse effects on prevailing market prices for Class A Ordinary Shares and/or Rights due to additional share issuance or debt incurrence.
• Default and foreclosure on assets if operating revenues after a Business Combination are insufficient to repay debt obligations.
• Increased vulnerability to adverse changes in general economic, industry, and competitive conditions, as well as government regulation.
• The Sponsor's ability to satisfy indemnification obligations for claims reducing the Trust Account balance is not assured, as their only assets are believed to be company securities.

Future Outlook

The company intends to complete its initial Business Combination with Merlin Labs, Inc. before the end of the Combination Period, which is November 4, 2026. The combined entity will operate as New Merlin Labs, Inc. The company may need to raise additional capital to meet working capital needs if the Business Combination is not consummated, and management plans to address the going concern uncertainty through the Business Combination.

Management Comments

• Management plans to address the substantial doubt about the company's ability to continue as a going concern through a Business Combination.
• Management believes the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation.

Industry Context

As a Special Purpose Acquisition Company (SPAC), Inflection Point Acquisition Corp. IV operates within a highly competitive and time-sensitive segment of the financial market. The proposed merger with Merlin Labs, Inc. positions the combined entity within the technology, media, and telecommunications (TMT) sector, a common focus for SPACs seeking high-growth potential. The pre-PIPE and Series A Preferred Stock investments reflect ongoing private market interest in technology companies, even as SPACs face increased scrutiny and redemption rates. The company's liquidity challenges and going concern warning are not uncommon for SPACs nearing their liquidation deadline without a completed transaction, highlighting the inherent risks of the SPAC model.

Comparison to Industry Standards

• The company must complete its initial Business Combination within 24 months of its IPO (by November 4, 2026) to avoid mandatory liquidation, which is a standard SPAC completion window.
• The Nasdaq 36-Month Requirement for SPACs to complete a business combination is a critical listing standard, and failure to meet it would result in delisting.
• The redemption value of Class A ordinary shares at approximately $10.39 per share as of September 30, 2025, reflects the interest earned on the Trust Account, which is a typical mechanism for SPACs to preserve shareholder value prior to a business combination.

Management Changes

Corporate Governance

Legal Proceedings

• No material litigation is currently pending or contemplated against the company or its officers/directors.

Related Party Transactions

• The Sponsor (Bleichroeder Sponsor 1 LLC) initially purchased 7,187,500 founder shares for $25,000 and an additional 2,395,833 founder shares, totaling 9,583,333 founder shares (adjusted to 8,333,333 after forfeiture).
• The Sponsor purchased 425,000 Private Placement Units for $4,250,000 simultaneously with the IPO.
• Inflection Point Fund I LP, an affiliate of a member of management, indirectly purchased all 425,000 Private Placement Units and holds membership interests in founder shares.
• The Sponsor, officers, and directors have agreed to waive redemption rights for their founder shares, private placement shares, and public shares in connection with the Business Combination or certain amendments to the articles of association.
• The Sponsor, officers, and directors have waived rights to liquidating distributions from the Trust Account for founder shares and private placement shares if the Business Combination is not completed within the Completion Window.
• The Sponsor has agreed to be liable for claims by third parties that reduce the Trust Account below $10.00 per public share, though the company cannot assure the Sponsor's ability to satisfy these obligations.
• The Sponsor transferred 110,000 and 500,000 Class A Units (representing an indirect interest in founder shares) to individuals on August 12, 2025, and September 22, 2025, respectively. The expense for these transfers will be recorded when the business combination becomes probable.
• The Sponsor had loaned the company up to $750,000 for IPO expenses, which was repaid on November 4, 2024.
• The Sponsor or affiliates may provide Working Capital Loans up to $2,500,000, with up to $750,000 from Inflection Point, convertible into private placement units at $10.00 per unit.

Stakeholder Impact

• Shareholders: Public shareholders will have the opportunity to redeem their shares in connection with the Business Combination. The value of their shares is tied to the success of the merger and the post-combination company's performance. Founder shares and private placement shares are subject to lock-up periods and waivers of redemption rights.
• Employees: The Business Combination will result in the combined company operating through Merlin Labs and its subsidiaries, potentially impacting employees of both entities. New equity incentive and employee stock purchase plans are proposed for New Merlin Labs.
• Creditors: The proceeds in the Trust Account could become subject to claims of creditors, which could have priority over public shareholders' claims in certain circumstances.
• Underwriters: The deferred underwriting fee of $8,750,000 is contingent on the completion of the Business Combination. Cash underwriting fee payments have been deferred, impacting their cash flow timing.

Next Steps

• Obtain required shareholder approvals for the Merlin Labs Business Combination Agreement, Domestication, proposed charter and bylaws of New Merlin Labs, issuance of shares, equity incentive plans, and director appointments.
• Complete the Domestication process, changing the jurisdiction of incorporation from Cayman Islands to Delaware.
• Satisfy all customary closing conditions for the Merlin Labs Business Combination, including regulatory approvals and accuracy of representations and warranties.
• Complete the redemption of properly tendered Public Shares at least one day prior to the Domestication.
• The company will change its name to Merlin Labs, Inc. upon the closing of the Business Combination.
• The remaining $1,000,000 cash underwriting fee payments will commence on September 1, 2026, payable in equal monthly amounts over three months.

Key Dates

Recommendation

The company has announced a definitive business combination agreement with Merlin Labs, Inc., which is a significant step forward for a SPAC and typically a positive catalyst. However, the company explicitly states 'substantial doubt about the Company's ability to continue as a going concern' due to its working capital deficit and the mandatory liquidation deadline if the merger is not completed. While the merger agreement and associated financing (Pre-PIPE and Series A Preferred Stock Investment) provide a path to completion, the inherent risks of SPAC transactions, potential for high redemptions, and the going concern warning warrant a 'hold' recommendation. Investors should monitor the progress of the Business Combination, shareholder approval, and redemption rates closely before making further investment decisions.

Keywords

SPAC, Merlin Labs, Business Combination, 10-Q, SEC Filing, Acquisition, Technology, TMT Sector, Financial Report, Corporate Governance, Going Concern, Capital Raise